ARTICLE | Strategy

Combo deals

How Allergan quickly assembled a NASH tool kit with Tobira, Akarna deals

October 3, 2016 7:00 AM UTC

Allergan plc's two NASH acquisitions give it the second biggest pipeline for the indication and enough mechanisms to develop in-house combinations that could target multiple drivers of the disease pathophysiology.

Together, Allergan's Sept. 20 deals to acquire Tobira Therapeutics Inc. and Akarna Therapeutics Ltd. give the pharma three mechanisms in non-alcoholic steatohepatitis. Gilead Sciences Inc. has four, with the only overlap across the two companies being a farnesoid X receptor (FXR; NR1H4) agonist. ...